An interventional study of Prolonged Exposure Therapy for Posttraumatic Stress Disorder in PTSD, sponsored by Massachusetts General Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Stress Disorders, Post-Traumatic by Massachusetts General Hospital — 5 open to participants now, 9 under way, none of them phase 3. Stress Disorders, Post-Traumatic · Massachusetts General Hospital.
Among the 28 studies in Stress Disorders, Post-Traumatic by Massachusetts General Hospital, this one is the 20th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2022, is one of 15 with no phase, and was the 18th registered.
2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →5 of the 28 studies in Stress Disorders, Post-Traumatic by Massachusetts General Hospital are open now, in 2 countries. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18–55 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 18–65
Massachusetts General Hospital · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in South Africa
Ages 18+
By country, each count listing its studies:
Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 1 · Phase 4 8
First in 2002; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 69 across 2,203 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 57 across the 27 interventional studies, 107 across the 1 observational. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
4 of the studies in Stress Disorders, Post-Traumatic by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01075672Massachusetts General HospitalOutcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals | 2027-01 |
| NCT07260032Massachusetts General HospitalDetermining the Benefits of Exercise on Cardiovascular Risk in PTSD | 2027-01-31 |
| NCT05788302Massachusetts General HospitalMechanisms Underlying Efficacy of Prolonged Exposure | 2027-03-01 |
| NCT07079761Massachusetts General HospitalFacilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD. | 2027-04-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 28 studies in Stress Disorders, Post-Traumatic by Massachusetts General Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Proposed research will examine time-of-day effects on trauma-related fear extinction using Prolonged Exposure Therapy (PE) telemedicine for Posttraumatic Stress Disorder (PTSD) in the National Center for PTSD (NCPTSD). The primary mechanistic outcome measure will be change in psychophysiological reactivity to script-driven imagery (SDI-PR) measured, in person, at pre-treatment, after 5 PE sessions (mid-treatment), and after all 10 PE sessions (post-treatment). A secondary mechanistic outcome will be session-to-session reduction in peak subjective units of distress (SUDS) ratings to imaginal exposures. The primary clinical outcome will be change in Clinican Administered PTSD Scale (CAPS-5) severity score; a secondary clinical outcome will be session-to-session reduction in self-reported PTSD symptoms using the PTSD checklist (PCL-5). Participants meeting inclusion criteria (described below) will be randomized to either PE sessions that begin from 07:00 to a time no later than 2 hours past a participant's customary rise time, or to the last treatment session of the day beginning at 16:00 or later (26 per arm). Participants will complete daily at-home imaginal-exposure homework within the same time frame as their PE sessions are scheduled, i.e., within 2 hours of awakening for morning (AM) group and between 16:00 and 2 hours before bedtime for late afternoon (PM) group.
Proposed research will examine time-of-day effects on trauma-related fear extinction using PE therapy for PTSD in the National Center for PTSD (NCPTSD). The primary mechanistic outcome measure will be change in SDI-PR; a secondary mechanistic outcome will be session-to-session reduction in peak SUDS ratings to imaginal exposures. The primary clinical outcome will be change in CAPS-5 severity score; a secondary clinical outcome will be session-to-session reduction in self-reported PTSD symptoms (PCL-5). Participants meeting inclusion criteria (described below) will be randomized to either PE sessions that begin from 07:00 to a time no later than 2 hours past a participant's customary rise time, or to the last treatment session of the day beginning at 16:00 or later. Participants will complete daily at-home imaginal-exposure homework within the same time frame as their PE sessions are scheduled (i.e., within 2 hours of awakening for morning group and between 16:00 and 2 hours before bedtime for late afternoon group). The assessment schedule will be identical for all participants. Participants who meet study inclusion criteria at screening will first begin a 7-day, pre-study sleep-monitoring period with wrist actigraphy, sleep diaries and completion of a diurnal profile of salivary cortisol levels. Trauma-related fear will be assessed using the standard SDI procedures detailed below at pre-treatment, after 5 PE sessions (mid-treatment), and after all 10 PE sessions (post-treatment). The CAPS-5 will be administered at these same times. PCL-5 measurements will be obtained at each treatment session and SUDs will be obtained during all treatment sessions that include imaginal exposure (sessions 3-8). All SDI sessions will be carried out at a standardized time of day in the late-afternoon (15:00-17:00). PE treatment will be administered at a targeted rate of once per week. At each PE and assessment session, pre-session saliva samples will be obtained for cortisol measurement and normalized using the diurnal profile of cortisol obtained during the sleep-assessment week. Participants will wear the wrist actigraph and complete sleep diaries throughout PE. The diurnal cortisol profile will be repeated at the post-treatment assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
26 participants randomized to 10 weekly PE sessions in early morning (between 07:00-10:00) with homework exposures occurring occur at this same time of day.
Behavioral: Prolonged Exposure Therapy for Posttraumatic Stress Disorder
26 participants randomized to 10 weekly PE sessions in late afternoon (16:00 or later) with homework exposures occurring occur at this same time of day.
Behavioral: Prolonged Exposure Therapy for Posttraumatic Stress Disorder
Manualized procedures deliver ten 90-minute sessions targeted to occur weekly and administered via tele-health with the same study therapist. Session 1 will focus on psychoeducation. Session 2 involves construction of the in vivo exposure hierarchy. Sessions 3-10 focus on in-session imaginal exposures to the worst trauma memory for 45-60 min followed by 15-20 min of processing the imaginal exposure. For homework, participants will be instructed to confront situations on their hierarchy on a daily basis using recording of their imaginal exposure. Subjective Units of Distress (SUDS) ratings will be taken throughout imaginal exposure exercises.
Psychophysiological Reactivity to Script-driven Imagery (SDI-PR): Primary Mechanistic Outcome
This primary mechanistic outcome, measured before, midway and after treatment is a unitary discriminant canonical variable (SDI-PR) that measures psychophysiological reactivity while listening to 2 personalized recorded scripts that describe a participant's index trauma. For each of 3 physiological measures- heart rate (HR), skin conductance (SC),and corrugator EMG (cEMG)- a response (R) score is calculated as the difference between the average level during a 30s pre-script baseline phase and the average level during a 30s imagery phase. These 3 scores are averaged across the 2 scripts and combined using standardized weights as: SDI-PR = 0.29\*\[HRR\] +0.66\*\[SCR\] +0.38\*\[cEMGR\]. There is no absolute limit to how much physiological reactivity can increase in response to scripts, therefore, minimum and maximum scores do not exist. However, a proxy maximum and minimum SDI-PR was estimated using the largest and smallest SCR, HRR, and cEMGR in the study and are respectively, 35.041and -3.061.
Time frame: Outcome measure 1 assessed at pre-treatment (baseline), mid-treatment (week 5), and post-treatment (week 10).
Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders (DSM), Fifth Edition (CAPS-5): Primary Clinical Outcome
This primary clinical outcome is the gold standard clinical interview for assessing PTSD severity. In CAPS-5, each of the 20 symptoms of PTSD is rated on a 5-point severity scale ranging from 0 (absent) to 4 (extreme). Total scores range from 0 to 80.
Time frame: Outcome measure 2 assessed at pre-treatment (baseline), mid-treatment (week 5), and post-treatment (week 10).
PCL-5: PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders (DSM), Fifth Edition: Secondary Clinical Outcome
PCL-5 contains self-ratings of how much one is bothered by each of the 20 symptoms of PTSD on a 5-point severity scale ranging from 0 (Not at all) to 4 (extremely). Outcome measure 3 is the total PTSD severity score summing all 20 items. The range of total scores for the PCL-5 is 0-80.
Time frame: 10 weeks
SUDS: Secondary Mechanistic Outcome
A rating scale from 0 to 100 where zero represents no distress at all and 100 represents very extreme distress, fear, or anxiety. SUDS ratings are subjective and different individuals may rate the same situation differently. An individual anchors their own ratings with personal recollection of situations considered "No Distress" to "Moderate" to "Extreme Distress".
Time frame: Starting at PE Session 3 when exposures begin
| Milestone | Early Morning PE | Late Afternoon PE |
|---|---|---|
| Started | 14 | 15 |
| Completed | 9 | 7 |
| Not completed | 5 | 8 |
This primary mechanistic outcome, measured before, midway and after treatment is a unitary discriminant canonical variable (SDI-PR) that measures psychophysiological reactivity while listening to 2 personalized recorded scripts that describe a participant's index trauma. For each of 3 physiological measures- heart rate (HR), skin conductance (SC),and corrugator EMG (cEMG)- a response (R) score is calculated as the difference between the average level during a 30s pre-script baseline phase and the average level during a 30s imagery phase. These 3 scores are averaged across the 2 scripts and combined using standardized weights as: SDI-PR = 0.29\*\[HRR\] +0.66\*\[SCR\] +0.38\*\[cEMGR\]. There is no absolute limit to how much physiological reactivity can increase in response to scripts, therefore, minimum and maximum scores do not exist. However, a proxy maximum and minimum SDI-PR was estimated using the largest and smallest SCR, HRR, and cEMGR in the study and are respectively, 35.041and -3.061.
| score on a scale | Early Morning PE | Late Afternoon PE |
|---|---|---|
| pre treatment | 6.07 ± 5.90 | 2.57 ± 3.76 |
| mid treatment | 2.41 ± 1.58 | 1.61 ± 2.39 |
| post treatment | 1.89 ± 2.46 | 1.51 ± 2.01 |
This primary clinical outcome is the gold standard clinical interview for assessing PTSD severity. In CAPS-5, each of the 20 symptoms of PTSD is rated on a 5-point severity scale ranging from 0 (absent) to 4 (extreme). Total scores range from 0 to 80.
| score on a scale | Early Morning PE | Late Afternoon PE |
|---|---|---|
| pre treatment | 33.71 ± 8.69 | 35.40 ± 8.80 |
| mid treatment | 27.10 ± 15.05 | 28.25 ± 14.25 |
| post treatment | 20.22 ± 13.08 | 21.71 ± 16.88 |
PCL-5 contains self-ratings of how much one is bothered by each of the 20 symptoms of PTSD on a 5-point severity scale ranging from 0 (Not at all) to 4 (extremely). Outcome measure 3 is the total PTSD severity score summing all 20 items. The range of total scores for the PCL-5 is 0-80.
| score on a scale | Early Morning PE | Late Afternoon PE |
|---|---|---|
| pre treatment | 45.98 ± 16.992 | 46.75 ± 15.399 |
| PE session 1 | 42.64 ± 19.975 | 45.62 ± 13.333 |
| PE session 2 | 37.62 ± 21.066 | 43.54 ± 16.934 |
| PE session 3 | 36.67 ± 19.644 | 38.17 ± 15.959 |
| PE session 4 | 36.13 ± 13.861 | 36.00 ± 18.228 |
| PE session 5 | 32.67 ± 13.946 | 33.20 ± 16.694 |
| PE session 6 | 31.00 ± 21.610 | 35.00 ± 17.626 |
| PE session 7 | 27.33 ± 17.277 | 31.00 ± 18.735 |
| PE session 8 | 23.78 ± 12.347 | 27.14 ± 18.542 |
| PE session 9 | 23.78 ± 17.333 | 26.57 ± 19.069 |
| PE session 10 | 25.88 ± 17.299 | 30.50 ± 17.524 |
| PE session 11 | 23.63 ± 11.952 | 29.17 ± 16.786 |
| post treatment | 18.37 ± 11.880 | 24.83 ± 18.258 |
A rating scale from 0 to 100 where zero represents no distress at all and 100 represents very extreme distress, fear, or anxiety. SUDS ratings are subjective and different individuals may rate the same situation differently. An individual anchors their own ratings with personal recollection of situations considered "No Distress" to "Moderate" to "Extreme Distress".
| score on a scale | Early Morning PE | Late Afternoon PE |
|---|---|---|
| PE Session 3 | 85.00 ± 7.638 | 85.00 ± 9.354 |
| PE Session 4 | 81.67 ± 10.897 | 92.38 ± 11.563 |
| PE Session 5 | 78.13 ± 13.076 | 87.57 ± 15.904 |
| PE Session 6 | 66.11 ± 17.638 | 79.71 ± 21.654 |
| PE Session 7 | 60.00 ± 16.202 | 77.86 ± 23.384 |
| PE Session 8 | 62.22 ± 17.697 | 81.57 ± 21.462 |
| PE Session 9 | 61.25 ± 15.755 | 83.83 ± 21.264 |
| PE Session10 | 50.00 ± 14.880 | 83.00 ± 25.677 |
Collected over From time of enrollment until the post-treatment assessment, up to 30 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Early Morning PE | 0/14 (0%) | 1/14 (7.1%) | 2/14 (14.3%) |
| Late Afternoon PE | 0/15 (0%) | 0/15 (0%) | 1/15 (6.7%) |
| Event | Early Morning PE | Late Afternoon PE |
|---|---|---|
| hospitalizationSurgical and medical procedures | 1/14 | 0/15 |
| Event | Early Morning PE | Late Afternoon PE |
|---|---|---|
| physical or emotional distressPsychiatric disorders | 2/14 | 1/15 |
| ER visitSurgical and medical procedures | 1/14 | 1/15 |
| Covid exposureRespiratory, thoracic and mediastinal disorders | 1/14 | 0/15 |
| Age, Continuous(years) | Early Morning PE | Late Afternoon PE | Total |
|---|---|---|---|
| Mean | 36.31 ± 10.20 | 47.11 ± 13.73 | 41.69 ± 13.06 |
| Sex: Female, Male(Participants) | Early Morning PE | Late Afternoon PE | Total |
|---|---|---|---|
| Female | 7 | 4 | 11 |
| Male | 7 | 11 | 18 |
| Ethnicity (NIH/OMB)(Participants) | Early Morning PE | Late Afternoon PE | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 3 | 6 |
| Not Hispanic or Latino | 10 | 10 | 20 |
| Unknown or Not Reported | 1 | 2 | 3 |
| Race (NIH/OMB)(Participants) | Early Morning PE | Late Afternoon PE | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 4 | 5 |
| White | 10 | 7 | 17 |
| More than one race | 1 | 4 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — We will share data every January 15 and July 15 with the NIMH Data Archives (NDA) under a NIMH Data Repositories Data Submission Agreement between NIMH and VA Boston Health System (VABHS). Data sharing is required for all NIMH-funded research projects. The NDA DSA will be approved by the VABHS IRB. Each participant will be assigned Global Unique ID (GUID) and data shared will contain no identifiable information. Shared data will include scored psychophysiological, self-report instruments, cortisol, actigraphy, and fully de-identified demographic data.
Supporting information: Study protocol
Time frame: Study data will become available following the end of the study and the publication of results.
Access criteria: Investigators can apply to the NIMH Data Archive (NDA) for permission to use these data.
Data sharing details ↗ · nda.nih.gov
Ran from Jul 2022 to primary completion in Aug 2025, 37 months.
Results were first posted in Nov 2026, 1 year 3 months after primary completion.
Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's 37 months is close to that.
Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.
Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Sep 2027, on Nov 12, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stress Disorders, Post-Traumatic →
Massachusetts General Hospital →